Venous thrombosis risk during and after medical and surgical hospitalizations: The medical inpatient thrombosis and hemostasis (MITH) study

Ximena Jordan Bruno1,2,3 | Insu Koh4 | Pamela L. Lutsey5 | Robert F. Walker5 | Nicholas S. Roetker6 | Katherine Wilkinson4 | Nicolas L. Smith7,8 | Timothy B. Plante2,3 | Allen B. Repp2,3 | Chris E. Holmes2,3 | Mary Cushman2,3,4 | Nicholas L. Smith7,8,9 | Timothy B. Plante2,3 | Allen B. Repp2,3 | Chris E. Holmes2,3 | Mary Cushman2,3,4 | Neil A. Zakai2,3,4

1Hematology Oncology Division, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
2Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, Vermont, USA
3University of Vermont Medical Center, Burlington, Vermont, USA
4Department of Pathology & Laboratory Medicine, Larner College of Medicine, University of Vermont, Burlington, Vermont, USA
5Division of Epidemiology & Community Health, University of Minnesota, Minneapolis, Minnesota, USA
6Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA
7Department of Epidemiology, University of Washington, Seattle, Washington, USA
8Kaiser Permanente Washington, Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA
9Department of Veterans Affairs Office of Research and Development, Seattle Epidemiologic Research and Information Center, Seattle, Washington, USA

Abstract

Background: Thirty to seventy percent of all venous thromboembolism (VTE) events are associated with hospitalization. The absolute and relative risks during and after hospitalization are poorly characterized.

Objectives: Quantify the absolute rate and relative risk of VTE during and up to 3 months after medical and surgical hospitalizations.

Patients/Methods: We conducted an observational cohort study between 2010 and 2016 of patients cared for by the University of Vermont (UVM) Health Network’s primary care population. Cox proportional hazard models with hospitalization modeled as a time-varying covariate were used to estimate VTE risk.

Results: Over 4.3 years of follow-up, 55,220 hospitalizations (156 per 1000 person-years) and 713 first venous thromboembolism events (2.0 per 1000 person-years) occurred. Among individuals not recently hospitalized, the rate of venous thromboembolism was 1.4 per 1000 person-years and 71.8 per 1000 person-years during hospitalization. During the first, second, and third months after discharge, the rates...
INTRODUCTION

Venous thromboembolism (VTE) consists of deep venous thrombosis (DVT) and pulmonary embolism (PE) and affects approximately 1 million individuals in the United States annually resulting in 100,000 deaths. Unique among vascular diseases, VTE has effective pharmacologic prevention strategies (albeit at the cost of increased bleeding) and risk is often concentrated around identifiable and sometimes transient risk factors. Provoked VTE are those events in which one or more clear temporally associated risk factors are identified, for example surgery, fracture, or hospitalization.

Thirty to seventy percent of all VTE events are associated with hospitalization and the time periods after hospitalization. Efforts to prevent VTE in hospitalized patients include administration of low-dose anticoagulants, but the benefit of this strategy in the post-discharge period is less clear. According to recently published randomized clinical trials, extending thromboprophylaxis after hospital discharge does not provide clinical benefit and may result in excessive bleeding. This could be in part due to not selecting the patients at highest risk of VTE and lowest risk of bleeding.

To address the gap in contemporary knowledge of the relative and absolute contribution of hospitalization on VTE risk, we followed a cohort of individuals receiving primary care at sites affiliated with an academic medical center in Vermont. We sought to (1) determine the relative and absolute risk of VTE during and up to 3 months after hospitalization and (2) assess VTE risk by medical and surgical hospitalizations.

METHODS

Population

Individuals 18 years old and older who received at least one primary care visit at the UVM Health Network were included in the cohort. UVM Medical Center is a tertiary care hospital in northwestern Vermont that serves as the primary (and only) hospital and imaging center for Chittenden County, VT with a population of 164,572 (Figure 1). UVM Medical Center deployed the fully integrated Epic electronic medical record across its inpatient and ambulatory services in October 2010 (Epic Systems Corporation, Verona, WI). Thus, individuals receiving primary care with UVM providers have near complete capture of their healthcare utilization. Individuals with a past history of VTE defined per International Classification of Diseases, Ninth or Tenth Edition, Clinical Modification (ICD-9/10-CM) diagnosis codes occurring within the first 3 months of entry to the cohort were excluded from all analyses (codes listed in Tables S1 and S2).

Follow-up time

Patients entered the cohort at the time of their first encounter with a UVM primary care provider, on or after October 1, 2010, to the time of change to a non-UVM primary care provider, death, a VTE event, or December 31, 2016 (whichever occurred first). Admission
to the hospital included both 'observation' and inpatient admissions and follow-up continued after people were discharged from the hospital. Observation status corresponded to those patients who spent only one night at the hospital (Figure 2). Follow-up time in the hospital was defined as days between admission and discharge inclusive of the admission and discharge day. Subsequent 1-month (30-day) periods after discharge and up to 3 months were assessed as risk factors for VTE. If an individual was readmitted within the 3 months after discharge from the hospital, the follow-up accrued with the most recent hospitalization (Figures 2 and 3). All other time was considered “no recent hospitalization” time.

2.3 Outcome and risk factor ascertainment

Incident VTE was defined as having one inpatient or two outpatient VTE ICD-9/10-CM codes 7–185 days apart, and with an anticoagulation prescription occurring within 30 days of the index report. The event date was the first date of a positive code. This definition was previously shown to increase the positive predictive value for VTE to >90%. VTE were classified into mutually exclusive groups as (1) those occurring during hospitalization when VTE was identified more than 24 h after admission to the hospital; (2) those occurring during time periods after hospitalization, defined as successive 1-month intervals for the total of 3 months post discharge; and (3) those occurring with no hospitalization in the prior 3 months (Figure 2).

Hospitalization and the dates of hospitalization were identified from the electronic medical record, as were age at the time of cohort entry and biologic sex. Surgical and medical hospitalizations were defined by the discharge service regardless of whether procedures were performed during the hospitalization. Surgical services consisted of cardiothoracic surgery, orthopedic surgery, urologic surgery, vascular surgery, general surgery, trauma surgery, or surgical intensive care unit and medical services consisted of cardiology, hematology, oncology, internal medicine/family medicine, medical intensive care, or neurology.

2.4 Statistical analyses

We compared age, sex, follow-up time, and the type of hospitalization by VTE status using univariate analysis (χ² tests for categorical risk factors and two-tailed t-tests for continuous risk factors). Hazard ratios and 95% confidence intervals for the association between hospitalization and VTE incidence were estimated using age- and sex-adjusted Cox proportional hazards models. The main exposure...
windows of interest (time in the hospital and each of the successive 1-month periods after discharge [up to 3 months]) were modeled as time-varying covariates. Separate analyses were also conducted by hospitalization type (surgical or medical). If a person was readmitted to the hospital within 3 months of discharge, the risk reset to the appropriate variable (surgical or medical hospitalization and time periods after hospitalization). Three months after discharge, the exposure reset to no recent hospitalization (Figure 3). There was no missingness for age, sex, dates of hospitalization, discharge services, or discharge ICD codes. Statistical analyses were performed using R 3.5.1 (R Foundation for Statistical Computing).

3 | RESULTS

3.1 | Population

From October 2010 through December 2016, 82 735 individuals 18 and older were followed for a median of 4.2 years. Among those, 46 284 were women (56%) and the median age was 46. All individuals were residents of the state of Vermont and 72.6% were resident of Chittenden County, Vermont (Figures 1 and 2). Table 1 presents the baseline characteristics of the population stratified by those who had
and did not have VTE over follow-up as well as those who were hospitalised versus those who were not hospitalised during follow-up.

### 3.2 | Follow-up time, VTE events and hospitalizations

Over 354 022 person-years of follow-up there were 713 first VTE events among 82 735 individuals and 55 173 hospitalizations among 20 921 individuals (some individuals were hospitalized more than once). There were 42 470 hospitalizations with a medical discharge service and 12 703 with a surgical discharge service.

### 3.3 | VTE rate and incidence

The overall rate of VTE in the cohort was two events per 1000 person-years ([Table 2](#)). Among the 214 VTE events occurring during or 3 months after hospitalization, 47 (22%) occurred during hospitalization and 167 (78%) within 3 months after discharge. While 97% of the follow-up time occurred when individuals were not hospitalized (344 793 of 354 022 person-years), only 69% (499 of 713) of VTE events occurred outside of the context of hospitalization and the 3 months post-discharge.

### 3.4 | VTE rate and incidence by hospitalization status

In individuals who were not hospitalized and did not have a hospital discharge within the prior 3 months, there were 499 VTE events over 344 793 person-years of follow-up (1.4 VTE events per 1000 patient-years) ([Table 2](#)). The absolute rate of VTE was 71.8 per 1000 person-years during hospitalization (47 events among 655 person-years). Over the successive 1-month periods after discharge, the rates of VTE were: 35.1 per 1000 person-years (124 events over 3530 person-years) in month 1, 11.3 per 1000 person-years (31 events over 2746 person-years) in month 2, and 5.2 per 1000 patient-years (12 events over 2298 person-years) in month 3. The cumulative incidence of VTE during hospitalization and for 3 months afterwards was 0.39% (214 events among 55 173 hospitalizations). For medical hospitalizations the corresponding rates were 73.9 per 1000 patient-years during hospitalization and 36.6, 12.5 and 5.3 per 1000 patient-years for the successive 1-month periods after discharge. The cumulative incidence of VTE during and for 3-months after hospitalization was 0.38% (162 VTE among 42 470 medical hospitalizations) For surgical hospitalizations, these rates were 66.7 per 1000 patient-years during hospitalization and 30.8, 8.5, and 5.1 per 1000 patient-years for the successive 1-month periods after discharge ([Table 2](#)). The cumulative incidence of VTE for surgical hospitalization and the 3 months after discharge was 0.41% (52 VTE among 12 702 hospitalizations).

Using age- and sex-adjusted Cox proportional hazards models with hospitalization modeled as a time-varying covariate, and with those not hospitalized in the prior 3 months as the reference group, the hazard ratio of VTE for hospitalization was 38.0 (95% CI 28.0, 51.5). The hazard ratios of VTE were 18.4 (95% CI 15.0, 22.6) for the first month, 6.33 (95% CI 4.3, 9.0) for the second month, and 3.0 (95% CI 1.7, 5.4) for the third month post-discharge. For non-surgical hospitalizations, compared to those not hospitalized in this prior 3 months, the hazard ratio for VTE was 36.5 (95% CI 25.6, 51.9). For the subsequent 1-month periods after discharge versus those

| Timeframe          | Person-years follow-up | N of VTE | VTE per 1000 person-years | Age- and Sex-adjusted HR (95% CI) |
|--------------------|------------------------|----------|---------------------------|----------------------------------|
| **No recent hospitalization** | 344 793 | 499 | 1.4 | 1.0 (Reference) |
| **All hospitalizations** |            |        |                            |                                  |
| During hospitalization | 655 | 47 | 71.8 | 38.0 (28.0, 51.5) |
| Month 1 after discharge | 3530 | 124 | 35.1 | 18.4 (15.0, 22.6) |
| Month 2 after discharge | 2746 | 31 | 11.3 | 6.3 (4.3, 9.0) |
| Month 3 after discharge | 2298 | 12 | 5.2 | 3.0 (1.7, 5.4) |
| **Non-surgical hospitalizations** |            |        |                            |                                  |
| During hospitalization | 460 | 34 | 73.9 | 36.5 (25.6, 51.9) |
| Month 1 after discharge | 2622 | 96 | 36.6 | 17.4 (13.8, 21.9) |
| Month 2 after discharge | 1920 | 24 | 12.5 | 6.2 (4.1, 9.4) |
| Month 3 after discharge | 1518 | 8 | 5.3 | 2.7 (1.4, 5.5) |
| **Surgical hospitalizations** |            |        |                            |                                  |
| During hospitalization | 195 | 13 | 66.7 | 41.6 (24.0, 72.3) |
| Month 1 after discharge | 908 | 28 | 30.8 | 22.2 (15.2, 32.6) |
| Month 2 after discharge | 826 | 7 | 8.5 | 6.2 (3.0, 13.2) |
| Month 3 after discharge | 780 | 4 | 5.1 | 3.8 (1.4, 10.1) |
not within 3 months of a hospitalization, the respective hazard ratios were 17.4 (95% CI 13.8, 21.9), 6.2 (95% CI 4.1, 9.4), and 2.7 (95% CI 1.4, 5.5). The corresponding hazard ratios for surgical hospitalizations were 41.6 (95% CI 24.0, 72.3) during the hospitalization and 22.2 (95% CI 15.2, 32.6), 6.2 (95% CI 3.0, 13.2), and 3.8 (95% CI 1.4, 10.1) for subsequent 1-month periods after discharge.

4 | DISCUSSION

In a cohort of adults receiving primary care through the University of Vermont Health Network, hospitalization and the 3 months after hospitalization accounted for 31% of all VTE events, while only accounting for 3% of the total follow-up time. Hospitalization was associated with a dramatically increased risk of VTE, with a hazard ratio of 38.0, as compared with non-hospitalized time periods, and this risk remained elevated for at least 3 months after discharge, gradually diminishing over time.

These findings confirm and extend previous observations about risk for VTE in hospitalized patients and the persistence of risk after discharge.14 Our results revealed that hospitalized patients had an absolute rate of 71.8 VTE events per 1000 person-years, as compared to 1.4 VTE events per 1000 person-years with no recent hospitalization, corresponding to a 38.0-fold increased hazard of VTE while in the hospital. Similar to the current study, in a study based in Olmstead County, Minnesota in the 1980s, the absolute rate of VTE in hospitalized patients was 96 per 1000 person-years, which was approximately 100-fold greater than in those not hospitalized.15 In the prospective, IMPROVE study, the cumulative incidence of VTE occurring during a medical hospitalization or in the 3 months after discharge was 1%, with ~45% of these after discharge.16 This cumulative incidence in IMPROVE was higher than that reported in the current study (0.39%), likely because the IMPROVE study selected medical patients deemed at ‘higher’ VTE risk.

The current study differs from prior studies in that the proportion of hospital-associated VTE events occurring post-discharge is higher. However, the IMPROVE study selected sicker hospitalized patients by requiring a minimum length of hospital stay and so should not be used to estimate the risk for all hospitalizations. Secular trends in the average length of hospitalization would also be expected to impact VTE rates and incidence patterns; the current average length of stay for medical admissions is 4–5 days (similar to that observed here) in comparison to 5–8 days 10 years ago.17 Length of stay is nowadays considered a quality measurement and there has been significant efforts nationwide to decrease this number18 however in terms of thrombosis risk this trend may result in shifting the risk of VTE to the immediate post-discharge period.19 In prior studies, half of hospital-acquired VTE events occurred by hospital-day 5,20 Mirroring the current study, a similar proportion of hospital-associated VTE events (70%) occurring after discharge was reported in a contemporary study of unselected hospitalizations from public hospitals in New South Wales, Australia.8 This suggests that shorter hospital stays have moved the risk of hospital-associated VTE from the inpatient to the post-discharge setting. The risk of post-discharge VTE was the justification for trials assessing the efficacy of post-discharge VTE prophylaxis with apixaban, betrixaban, rivaroxaban, and enoxaparin in medical patients.21–25 These trials revealed that bleeding is a real concern in this population22 and that post-discharge prophylaxis does not reduce VTE in everyone21,25 but may benefit some patient populations.23 Overall, given the unclear benefit and inability to define a population who may benefit, American Society of Hematology’s guidelines currently advise to not continue thromboprophylaxis in the post-discharge period.9,26

Our analysis has strengths and limitations. The strengths of our study are the size of the cohort, the number of VTE events, and appropriate statistical methods to capture the time-varying nature of hospitalization as a risk factor for VTE. We may have missed some VTE events diagnosed outside the UVM Health Network. However, given that the overall rate of VTE is consistent with the general population and the consistency of our results with the prior literature, this unlikely biased our results to a significant degree.6 Another source of potential bias is that we followed a population engaged with health care that may be sicker (and have a higher baseline rate of VTE) than the general population; however, we would expect that this would bias our results for the association of hospitalization versus no hospitalization towards the null. Further, given we did not adjudicate VTE events, some VTE events are likely misclassified. However, prior studies have demonstrated a high positive predictive value for the definition we used.12 We did not perform extensive risk factor adjustment because our goal was to determine the impact of hospitalization as a risk factor for VTE and not the reasons underlying the association. As the population included people who were hospitalized and those not hospitalized, there is likely under-ascertainment of co-morbid conditions in those not hospitalized making this study design less than ideal for determining the reasons behind hospitalization as a risk factor for HA-VTE. Similarly, repeated hospitalization over short periods of time is likely a risk factor for hospital-associated VTE but the current study is underpowered to address this. Further research will determine higher or lower risk groups for hospital-associated VTE.

In conclusion, risk of VTE is dramatically higher during hospitalization and in the 3 months after hospitalization, with risk gradually decreasing over time. In contrast to prior studies, this contemporary study demonstrates a greater proportion of VTE events occurring after discharge than during hospital stay, highlighting the importance of further research into risk assessment and preventive interventions as a means of reducing the incidence of potentially preventable VTE. As reflected by the American Society of Hematology’s guidelines on VTE prophylaxis, post-discharge prophylaxis is not currently the standard of care. However, the current findings provide a strong rationale and foundation for future studies to refine post-discharge VTE risk assessment and design possible interventions to reduce VTE risk.

ACKNOWLEDGEMENTS

This study was funded by grant R01-HL141290 (N.A. Zakai) and R01-HL131579 (P.L. Lutsey) from the National Heart, Lung, and
Blood Institute, National Institutes of Health, Bethesda, MD USA. The sponsor had no role in the analysis or interpretation of the data and the views presented in this manuscript do not necessarily reflect those of the sponsor. We appreciate and acknowledge the support and expertise of Mr. Michael Gianni, Senior Measurement Analyst and the Data Management Office at the University of Vermont Health Network.

CONFLICT OF INTEREST
Ximena Jordan Bruno, Insu Koh, Pamela L. Lutsey, Robert F. Walker, Nicholas S. Roetker, Katherine Wilkinson, Nicholas L. Smith, Timothy B. Plante, Allen B. Repp, Chris E. Holmes, Mary Cushman, and Neil A. Zakai report no conflicts of interest.

INFORMED CONSENT
The research reported here conformed to the tenants of the Declaration of Helsinki and was determined exempt by the University of Vermont Institutional Review Board based on exemption category 4 under the 2018 Common rule.

AUTHOR CONTRIBUTIONS
Secured Funding: N.A. Zakai, P.L. Lutsey. Concept and Design: X. Jordan Bruno, Insu Koh, Pamela L. Lutsey, Robert F. Walker, Nicholas S. Roetker, Katherine Wilkinson, Nicholas L. Smith, Timothy B. Plante, Allen B. Repp, Chris E. Holmes, Mary Cushman, and Neil A. Zakai.

REFERENCES
1. Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. Am J Prev Med. 2010;38:5495-501. doi:10.1016/j.amepre.2009.12.017
2. Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med. 2004;117:19-25. doi:10.1016/j.amjmed.2004.01.018
3. Streiff MB, Brady JP, Grant AM, et al. CDC Grand Rounds: preventing hospital-associated venous thromboembolism. MMWR Morb Mortal Wkly Rep. 2014;63:190-193.
4. Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141:e139-e596. doi:10.1161/CIR.0000000000000757
5. Stein PD, Beemath A, Olson RE. Trends in the incidence of pulmonary embolism and deep venous thrombosis in hospitalized patients. Am J Cardiol. 2005;95:1525-1526. doi:10.1016/j.amjcard.2005.02.030
6. Douce DR, Holmes CE, Cushman M, MacLean CD, Ade S, Zakai NA. Risk factors for cancer-associated venous thromboembolism: the venous thromboembolism prevention in the ambulatory cancer clinic (VTE-PACC) study. J Thromb Haemost. 2019;17:2152-2159. doi:10.1111/jth.14614
7. Hull RD, Merali T, Mills A, Stevenson AL, Liang J. Venous thromboembolism in elderly high-risk medical patients: time course of events and influence of risk factors. Clin Appl Thromb Hemost. 2013;19:357-362. doi:10.1177/1076029213481105
8. Stubbs JM, Assareh H, Curnow J, Hitos K, Achat HM. Incidence of in-hospital and post-discharge diagnosed hospital-associated venous thromboembolism using linked administrative data. Intern Med J. 2018;48:157-165. doi:10.1111/imj.13679
9. Schunemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018;2:3198-3225. doi:10.1182/bloodadvances.2018022954
10. Ramacciotti E, Fareed J. Rivaroxaban for post-discharge thromboprophylaxis: the MARINER trial. Int Angiol. 2018;37(427-30). 10.23736/S0392-9590.18.04069-5
11. Bureau USC. 2010 Census. In: Bureau USC, ed., 2010.
12. Zakai NA, Walker RF, MacLehose RF, Adam TJ, Alonso A, Lutsey PL. Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism. J Thromb Haemost. 2018;16:2403-2412. doi:10.1111/jth.14303
13. Sanfilippo KM, Wang TF, Gage BF, Liu W, Carson KR. Improving accuracy of International Classification of Diseases codes for venous thromboembolism in administrative data. Thromb Res. 2015;135:616-620. doi:10.1016/j.thromres.2015.01.012
14. Amin AN, Varker H, Prinic N, Lin J, Thompson S, Johnston S. Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients. J Hosp Med. 2012;7:231-238. doi:10.1002/jhm.1002
15. Heit JA, Melton LJ 3rd, Lohse CM, et al. Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin Proc. 2001;76:1102-1110. doi:10.4065/76.11.1102
16. Spyropoulos AC, Anderson FA Jr, FitzGerald G, et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011;140:706-714. doi:10.1378/chest.110444
17. Gillum BS, Graves EJ, Jean L. Trends in hospital utilization: united states, 1988–92. Vital Health Stat. 1996;13:1-71.
18. Doctoroff L, Hsu DJ, Mukamal KJ. Trends in prolonged hospitalizations in the United States from 2001 to 2012: a longitudinal cohort study. Am J Med. 2017;130(483):e1-7. doi:10.1016/j.amjmed.2016.11.018
19. Southern WN, Berger MA, Bellin EY, Haipern SM, Arnsten JH. Hospitalist care and length of stay in patients requiring complex discharge planning and close clinical monitoring. Arch Intern Med. 2007;167:1869-1874. doi:10.1001/archinte.167.17.1869
20. Zakai NA, Callas PW, Repp AB, Cushman M. Venous thrombosis risk assessment in medical inpatients: the medical inpatients and thrombosis (MITH) study. J Thromb Haemost. 2013;11:634-641. doi:10.1111/jth.12147
21. Cohen AT, Harrington RA, Goldhaber SZ, et al. Extended Thromboprophylaxis with Betrixaban in acutely Ill medical patients. N Engl J Med. 2016;375:534-544. doi:10.1056/NEJMoa1601747
22. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365:2167-2177. doi:10.1056/NEJMoa1110899
23. Hull RD, Schellong SM, Tapson VF, et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010;153:8-18. doi:10.7326/0003-4819-153-1-20100 7060-00004
24. Raskob GE, Spyropoulos AC, Zrubek J, et al. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high
risk of VTE. Design, rationale, and clinical implications. Thromb Haemost. 2016;115:1240-1248. doi:10.1160/TH15-09-0756

25. Spyropoulos AC, Ageno W, Albers GW, et al. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N Engl J Med. 2018;379:1118-1127. doi:10.1056/NEJMoa1805090

26. Wiercioch W, Nieuwlaat R, Akl EA, et al. Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences. Blood Adv. 2020;4:2351-2365. doi:10.1182/bloodadvances.2020001768

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.